FAQ

Synagis

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2016
0519982016

Related topics

Related topics

1 relation

Broader (1)

palivizumab

Related mentions per year

Related mentions per year

1972-2018
197019801990200020102020
Synagis
palivizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
EMLA cream and nitrous oxide to alleviate pain induced by palivizumab (Synagis) intramuscular injections in infants and young children.
OBJECTIVE Palivizumab (Synagis [Abbot Laboratories, Kent, United Kingdom]) is recommended for the prevention of severe lower… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2005
2005
Safety and immunogenicity of palivizumab (Synagis) administered for two seasons.
To evaluate the safety and immunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5… (More)
Is this relevant?
2004
2004
Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory… (More)
Is this relevant?
2004
2004
Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
OBJECTIVE Use of palivizumab prophylactic therapy reduces the occurrence of hospitalizations for serious respiratory syncytial… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2003
2003
Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro.
Human metapneumovirus (hMPV) is a newly recognized pathogen that like its better-known relative, human respiratory syncytial… (More)
Is this relevant?
Review
2002
Review
2002
Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV.
Palivizumab (Synagis; Abbott Laboratories), a humanized, monoclonal antibody, prevents lower respiratory tract infection by… (More)
Is this relevant?
2001
2001
Developing a synagis clinic for respiratory syncytial virus prophylaxis.
Respiratory Syncytial Virus (RSV) can be devastating to premature infants and children with chronic lung disease. Palivizumab… (More)
Is this relevant?
2000
2000
Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions.
OBJECTIVE We developed an enzyme-linked immunosorbent assay (ELISA) for the quantitation of respiratory syncytial virus (RSV) in… (More)
Is this relevant?
1999
1999
Comparability testing of a humanized monoclonal antibody (Synagis) to support cell line stability, process validation, and scale-up for manufacturing.
Biochemical and functional testing of a humanized monoclonal antibody directed against Respiratory Syncytial Virus (Synagis) has… (More)
Is this relevant?
1999
1999
Synagis: an anti-RSV monoclonal antibody.
Palivizumab is a new anti-RSV monoclonal antibody product indicated for the prevention of serious lower respiratory tract disease… (More)
Is this relevant?